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Objectives: In Saudi Arabia, viral hepatitis ranked the second most common reportable viral
disease in 2007, with almost 9000 new cases diagnosed in that year. The objective of this study
was to determine the incidence trends of viral hepatitis seropositivity among the population
served by the National Guard Health Affairs (NGHA) hospitals in the central, eastern, and western
Saudi Arabia regions.
Methods: The surveillance system at King Abdulaziz Medical City in Riyadh receives weekly reports
of laboratory confirmed hepatitis A virus (HAV), hepatitis B virus (HBV), and hepatitis C virus (HCV)
cases from all NGHA-served regions. In this study the viral hepatitis surveillance data for the period
from January 2000 through December 2007 were analyzed.
Results: Between 2000 and 2007, a total of 14 224 seropositive cases of viral hepatitis were
reported to the surveillance system. The average annual incidence of seropositivity per 100 000
served population was highest for HBV (104.6), followed by HCV (78.4), and lowest for HAV (13.6).
Saudis had higher HBVand HAV incidence, but lower HCV incidence compared to non-Saudis. Over
the eight years (2000—2007), the incidence of all three viral hepatitis types showed a 20—30%
declining trend. Only HAV incidence followed a clear seasonal cyclic pattern.
Conclusions: Despite the declining trend over the eight-year period, viral hepatitis, especially that
caused by HBV and HCV, remains a major public health problem in Saudi Arabia, and has probably
been underestimated in previous reports. There is a need for more comprehensive prevention
strategies.
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Viral hepatitis is caused by infection with any of at least five
distinct viruses, of which hepatitis A virus (HAV), hepatitis BPublished by Elsevier Ltd. All rights reserved.
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commonly identified worldwide. This disease represents a
major public health problem in Saudi Arabia. According to the
Saudi Ministry of Health (MOH) data, viral hepatitis ranked
the second most common reportable viral disease after
chickenpox in 2007, with almost 9000 new cases diagnosed
in that year (52% HBV, 32% HCV, and 16% HAV).1 In Saudi
Arabia, HBV and HCV are major causes of disease requiring
liver transplantation and of hepatocellular carcinoma,
resulting in the need for considerable healthcare
resources.2—4
The epidemiology of viral hepatitis in Saudi Arabia has
undergone major changes, concurrent with major socioeco-
nomic developments over the last two to three decades.
Since the 1980s, Saudi Arabia has been known as a high HBV
endemic area.5 However, starting in 1990, HBV vaccine has
been administered to all Saudi infants/children.6 This has
been associated with a reportable decline in hepatitis B
surface antigen (HBsAg) seroprevalence, mainly in chil-
dren.1,6—8 HCV remains a major public health problem in
Saudi Arabia, especially among certain high risk groups.9,10
Moreover, the reported high rate of decline in HCV in some
prevalence studies over the last decade9,11 has not been
confirmed in a recent large incidence report,12 nor in the
Saudi MOH data.1 Recently, HAV vaccine has been added to
the Saudi list of infant/childhood immunizations. Universal
immunization against HAV in Saudi Arabia was recently
recommended after a shift in the HAV epidemiology in the
country, reducing it from a classic high endemic area to a
low/moderate endemic area.13,14
With few exceptions,6,15 the published rates of viral
hepatitis in Saudi Arabia have mainly been based on pre-
valence studies. While these studies may be good for mea-
suring viral hepatitis burden, they have limited ability to
measure the actual disease risk in the community or the
effectiveness of immunization programs. These prevalence
studies are typically retrospective, have small sample sizes,
evaluate selected populations, or cover localized geographic
areas. Together with the different methods used, these
limitations may impede the ability to study temporal trends
in viral hepatitis rates. The objective of the current studywas
to report the incidence trends of viral hepatitis seropositiv-
ity, using a standardized methodology, for the population
served by the National Guard Health Affairs (NGHA) hospitals
in different regions of Saudi Arabia between 2000 and 2007.
Methods
Four NGHA hospitals (approximately 2000 beds in total) and
73 primary care centers provide medical care for almost a
million National Guard employees and their dependents
(spouses, children, and parents) in the central, eastern,
and western regions of Saudi Arabia. The population served
by the NGHA (97% Saudi) represents about 4% of the total
population of Saudi Arabia (23.7 million in 2006) and has an
annual growth rate of 2.9%. The care provided by the NGHA
hospitals and primary care centers ranges from primary and
preventive care to tertiary care.
TheDepartment of Infection Prevention andControl at King
Abdulaziz Medical City (KAMC) in Riyadh, Saudi Arabia has a
surveillance system that receives weekly reports of reportableinfectious diseases, including viral hepatitis caused by HAV,
HBV, and HCV, from all NGHA-served regions. The surveillance
methodologyusedwasconsistent throughout the studyperiod.
A case was considered ‘suspected viral hepatitis’ if the World
Health Organization (WHO)-recommended acute viral hepati-
tis clinical case definition was met.16 The case definition was
considered met when there was an acute illness that typically
included acute jaundice, dark urine, anorexia, malaise,
extreme fatigue, and right upper quadrant tenderness. Only
viral hepatitis cases that were laboratory confirmed, regard-
less of clinical signs and symptoms,were reported to the KAMC
surveillance system. A case was considered to be HAV-positive
if tests for anti-HAV immunoglobulin M (IgM) were positive,
considered HBV-positive if tests for HBsAg were positive, and
considered HCV-positive if tests for anti-HCV were positive,
using ELISA. Seropositive cases of viral hepatitis were reported
by laboratory personnel as part of intensive passive surveil-
lance, which took place in multiple situations including the
recruitment of new military or civilian employees, when
medical care for a related condition was sought, during
antenatal care (HBV only), in those attending hemodialysis
units, in those undergoing organ transplantation or donating
blood, or during the conducting of an outbreak investigation
(mainly HAV).
For the purpose of this report, viral hepatitis surveillance
data for the period from January 2000 through December
2007 were analyzed. Incidence trends refer to rates over time
of newly diagnosed seropositive cases of viral hepatitis. The
incidence rate for a specified type of viral hepatitis for a
certain year and/or demographic group (gender, age group,
nationality, or NGHA region of reporting) was calculated by
dividing the number of reported seropositive cases for that
type of viral hepatitis for that year and/or demographic
group by the corresponding estimated NGHA-served popula-
tion for that year and/or demographic group, then multiplied
to give the rate per 100 000. The incidences over the eight
years of surveillance (2000—2007) were plotted to detect any
upward or downward trends. Duplicate cases (the same
person reported more than one time with the same type
of hepatitis) were not included in the analysis.
Epi Info software (version 6.04; CDC, Atlanta, GA, USA)
was used to manage the surveillance database. Demographic
characteristics including age, gender, nationality, and report-
ing NGHA region were compared between those with
reported HAV, HBV, and HCV. Differences in incidence by
demographic characteristics for each viral hepatitis type
were examined. The Chi-square test was used to test for
significant differences in categorical variables, while analysis
of variance (ANOVA) or the Kruskal—Wallis test, as appro-
priate, were used to test for significant differences in con-
tinuous variables. All p-values were two-tailed. A p-value of
<0.05 was considered as significant. SPSS software (version
15.0; SPSS Inc., Chicago, IL, USA) was used for all statistical
analyses.
Results
During the eight years of surveillance (2000—2007), a total of
14 224 seropositive cases of viral hepatitis were reported to
the KAMC surveillance system. HBV was the most frequent
viral hepatitis type reported (n = 7572, 53%), followed by HCV
Table 2 Average annual incidence of HAV, HBV, and HCV
seropositivity per 100 000 NGHA-served population between
2000 and 2007 by demographic characteristicsa
HAV HBV HCV
Average annual incidence 13.6 104.6 78.4
Incidence by age group
<15 years 27.9 5.6 2.8
15 years 4.1 169.8 128.2
p < 0.001 p < 0.001 p < 0.001
Incidence by gender
Males 14.7 123.0 76.8
Females 12.4 85.5 80.1
p = 0.008 p < 0.001 p = 0.110
Incidence by nationality
Saudi 13.7 105.3 76.8
Non-Saudi 7.4 84.0 130.7
p = 0.012 p = 0.002 p < 0.001
Incidence by NGHA region
Central 14.2 113.8 99.8
Western 11.4 115.6 59.0
Eastern 15.1 53.8 34.9
p = 0.006 p < 0.001 p < 0.001
HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C
virus; NGHA, National Guard Health Affairs.
a Testing differences using the Chi-square test.
Table 1 Demographic characteristics of HAV, HBV, and HCV seropositive cases reported to the King Abdulaziz Medical City
surveillance system between 2000 and 2007
HAV HBV HCV p-Valuea
Mode of yearly rank among reportable infectious diseases 9 th 2nd 3 rd p < 0.001b
Total number of cases 981 7572 5675 p < 0.001
Age, years (mean  SD) 11.0  10.5 37.2  16.2 49.9  17.2 p < 0.001c
Cases by age group, n (%)
< 15 years 803 (81.9%) 162 (2.1%) 81 (1.4%) p < 0.001
15 years 178 (18.1%) 7410 (97.9%) 5594 (98.6%)
Cases by gender, n (%)
Males 542 (55.2%) 4540 (60.0%) 2834 (49.9%) p < 0.001
Females 439 (44.8%) 3032 (40.0%) 2841 (50.1%)
Cases by nationality, n (%)
Saudi 965 (98.4%) 7394 (97.6%) 5391 (95.0%) p < 0.001
Non-Saudi 16 (1.6%) 182 (2.4%) 284 (5.0%)
Cases by NGHA region, n (%)
Central 584 (59.5%) 4695 (62.0%) 4118 (72.6%) p < 0.001
Western 222 (22.6%) 2258 (29.8%) 1153 (20.3%)
Eastern 175 (17.8%) 623 (8.2%) 404 (7.1%)
HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C virus; SD, standard deviation; NGHA, National Guard Health Affairs.
a Testing differences between viral hepatitis types using the Chi-square test unless stated otherwise.
b Kruskal—Wallis test.
c ANOVA (analysis of variance) test.
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served population ranged from about 816 000 in 2000 to 998
000 in 2007, with an average annual served population of 904
000 during the study period. The age of viral hepatitis cases
was significantly different between the different viral types
( p < 0.001), with HAV in the youngest (11.0  10.5 years),
followed by HBV (37.2  16.2 years), and HCV in the oldest
(49.9  17.2 years) (Table 1). Those aged 15 years repre-
sented 18.1% of HAV cases, 97.9% of HBV cases, and 98.6% of
HCV cases (Table 1). Gender, nationality, and reporting NGHA
region were significantly different between the different
types of viral hepatitis ( p < 0.001 for each). The majority
of HBV and HAV, but not HCV cases, were male. The majority
of hepatitis cases were reported in those of Saudi nationality,
and the majority of cases were reported from the Central
NGHA region (Table 1).
The average annual seropositivity incidence was highest
for HBV (104.6 per 100 000), followed by HCV (78.4 per 100
000), and lowest for HAV (13.6 per 100 000) (Table 2). The
eight-year (2000—2007) incidence trends (per 100 000) for
HAV, HBV, and HCV seropositivity were studied (Figures 1—3).
HAV incidence was almost 7-fold higher in those who were
aged <15 years compared to those who were aged 15 years
(annual average incidence of 27.9 vs. 4.1 per 100 000;
p < 0.001). HAV incidence was significantly higher in males
than females, Saudis than non-Saudis, and in the central and
eastern regions than the western region (Table 2). Over these
eight years, the incidence of HAV seropositivity decreased by
30% (11.4 per 100 000 in 2000 vs. 8.0 per 100 000 in 2007;
Figure 1). When the incidence was stratified by age group,
HAV incidence decreased by 42% in those aged <15 years and
increased by 61% in those aged 15 years. All age groups
experienced a markedly increased HAV incidence in 2004
compared to 2003 (outbreak), which was cleared by 2007in all age groups combined and in those who were <15 years
old, but not in those who were aged15 years (Figure 1). HAV
incidence followed a seasonal cyclic pattern, with peaks in
March and September (Figure 4).
Figure 2 Incidence trends of HBV seropositivity per 100 000 NGHA-served population (by age group) between 2000 and 2007.
Figure 1 Incidence trends of HAV seropositivity per 100 000 NGHA-served population (by age group) between 2000 and 2007.
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higher in those who were aged 15 years compared to those
who were <15 years (annual average incidence of 169.8 vs.
5.6 per 100 000; p < 0.001). HBV incidence was significantly
higher in males than females, Saudis than non-Saudis, and in
central and western regions than the eastern region
(Table 2). Between 2000 and 2007, HBV incidence decreased
by 21% for all age groups combined (from 124.3 to 98.1 per
100 000), by 19% for those who were aged 15 years (from
195.9 to 158.7 per 100 000), and by 78% for those who wereFigure 3 Incidence trends of HCV seropositivity per 100 000 NGaged <15 years (from 16.7 to 3.6 per 100 000) (Figure 2).
There was no clear seasonal variation in HBV incidence
(Figure 4).
The incidence of HCV seropositivity was almost 45-fold
higher in those who were aged 15 years compared to those
who were aged<15 years (annual average incidence of 128.2
vs. 2.8 per 100 000; p < 0.001). HCV incidence was similar in
males and females, but higher in non-Saudis than Saudis and
in the central region than in the other regions (Table 2).
During the eight-year study period, HCV incidence decreasedHA-served population (by age group) between 2000 and 2007.
Figure 4 Seasonal variation in the incidence of seropositive cases of HAV, HBV, and HCV reported to the King Abdulaziz Medical City
surveillance system between 2000 and 2007.
Incidence trends of viral hepatitis A, B, and C seropositivity over eight years of surveillance in Saudi Arabia e119by 30% (from 98.0% to 68.4% per 100 000). The reduction was
generally similar in those who were aged <15 and 15 years
(23% and 31%, respectively (Figure 3)). There was no clear
seasonal variation in HCV incidence (Figure 4).
Discussion
The current study reports for the first time, the eight-year
incidence trends of HAV, HBV, and HCV seropositive viral
hepatitis in a large population served by the NGHA hospitals
in the central, eastern, and western regions of Saudi Arabia.
The consistency of the surveillance methodology throughout
the study period, including the diagnostic tests used, prob-
ably reduces the possibility of biased upward or downward
trends. Between 2000 and 2007, the incidence of viral hepa-
titis seropositivity for all three virus types showed 20—30%
declining trends. Similarly, a comprehensive review of pre-
valence studies of viral hepatitis conducted in Saudi Arabia in
the 1980s and 1990s showed a more than 50% decline in all
viral hepatitis types.8 The age group that included children
<15 years was that which showed the greatest HBV incidence
decline, probably due to the universal infant/child immuni-
zation program started in 1990 in Saudi Arabia.17 The modest
HCV incidence reduction, which was similar in those aged
<15 and15 years, may be explained by the improved safety
of blood products, strict infection control precautions for
high risk medical services such as hemodialysis and dental
services, enforcing premarital blood screening, and finally
increased awareness of dangerous practices such as needle-
sharing among drug abusers, cautery, and blood letting. The
HAV incidence reduction was driven mainly by the decline in
incidence in children aged <15 years who suffered the major
part of the disease burden. This reduction may be attributed
to the improvements in environmental sanitation that have
accompanied major socioeconomic developments in Saudi
Arabia over recent decades.13
Despite the declines in incidence, the current report
confirms that seropositive viral hepatitis, especially that
caused by HBV and HCV, remains a major public health
problem in Saudi Arabia, and was probably underestimated
by the national surveillance system. For example, when
comparing the 2007 incidence from this study with the2007 Saudi MOH data,1 the incidences of HBV and HCV were
5- to 6-fold higher in our study (98.1 vs. 18.6 per 100 000 for
HBVand 68.4 vs. 11.7 per 100 000 for HCV). HAV incidence, on
the other hand, was roughly similar (8.0 in our study vs. 5.7
per 100 000), and the 2004 HAV outbreak shown in this report
was documented in the Saudi MOH data, at a lower magni-
tude though.1 Supporting our observation of national under-
estimation of HBV and HCV risk in Saudi Arabia, a recent
report from the eastern region estimated the average annual
incidence as 9.5 for HAV, 46.0 for HBV, and 37.7 for HCV per
100 000 population served by hospitals of the Saudi Aramco
Medical Services Organization.15 Irrespective of the report
used, the incidence of seropositive viral hepatitis in Saudi
Arabia is remarkably higher than the incidence in the USA,18
which has one of the world’s lowest rates, pointing to the
scope of the problem in Saudi Arabia and the need for more
comprehensive prevention strategies.
The higher incidence shown in this report may be due to
the intensive passive surveillance undertaken in the well-
defined NGHA population that occurred in multiple situa-
tions, including the recruitment of new military or civilian
employees, when medical care for a related condition was
sought, during antenatal care (HBVonly), in those attending
hemodialysis units, in those undergoing organ transplanta-
tion or donating blood, or during the conducting of an
outbreak investigation (mainly HAV). This exhaustive sur-
veillance may have detected more cases than would be
expected from less intensive surveillance, especially as
the laboratory-based diagnosis of HBV and HCV used in this
and other reports, detects newly developed as well as
previously undetected chronic cases. In addition, the inci-
dence of seropositive viral hepatitis could actually be higher
in the military population than in the rest of the Saudi
population.19—21
The current report shows that HBV was the most frequent
cause of viral hepatitis seropositivity, followed by HCV, and
lastly by HAV. Supporting our findings, prevalence studies on
Saudi blood donors over the last decade have shown higher
HBV prevalence (1.5—2.6%) compared to HCV prevalence
(0.4—1.1%).11,22,23 However, while the incidence of HAV
seropositivity was the lowest among the three studied viral
hepatitis types, prevalence studies have consistently shown
HAV to be the most prevalent viral hepatitis type. HAV
e120 Z.A. Memish et al.prevalence was recently estimated to be 29%,14 which is at
least 50% lower than that reported a decade earlier.13,24 This
can be explained by the fact that the surveillance methodol-
ogy used here and in other surveillance systems, frequently
misses many asymptomatic and sporadic cases common in
endemic areas. Interestingly, only HAV incidence followed a
clear seasonal cyclic pattern, with peaks in March and Sep-
tember. A similar pattern has been described in other coun-
tries.25,26 This may be related tomore children being exposed
during the mid-year, and summer vacations spent in more
endemic areas abroad.
In conclusion, this report describes the incidence trends of
seropositive viral hepatitis in a large population from differ-
ent regions of Saudi Arabia. Over the last eight years, the
incidences of all three types of viral hepatitis (caused by HAV,
HBV, and HCV) have shown 20—30% declining trends. Never-
theless, the current report confirms that viral hepatitis,
especially that caused by HBV and HCV, remains a major
public health problem in Saudi Arabia, and has probably been
underestimated in previous reports. There is a need for more
comprehensive prevention strategies. It is probably going to
take two to three decades before viral hepatitis prevalence
reflects the full stable effect of any prevention programs.
The effectiveness of such prevention programs can best be
measured by incidence studies.
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